A serological 2-year follow-up of 35 patients who had brucellosis with different clinical outcomes was performed. Patients were followed up by standard tube agglutination (STA) and 2-mercaptoethanol STA (2ME-STA) tests and by two enzyme-linked immunosorbent assays (ELISAs) to independently measure values of serum IgG to either lipopolysaccharide (LPS) or cytoplasmic proteins of Brucella. Whereas STA and 2ME-STA tests revealed characteristic antibody profiles for patients who recovered (group I), this was not the case for patients with persistent illness (group II) or patients with relapses (group III). On the other hand, titers measured by the 2ME-STA test were low or negative in 10 patients who had positive blood cultures. Levels of IgG antibodies to LPS and proteins in each group of patients exhibited characteristic changes. For group I, however, antibodies to proteins were better predictors of recovery, since titers reached negative values for five patients. Levels of IgG antibodies to LPS and proteins were persistently high in group II patients, and peaks in these antibody levels corresponded with relapses in group III patients. The determination of values of IgG antibodies to proteins by ELISA appears useful for the serological follow-up of patients with brucellosis.
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Human and animal infections caused by Brucella are distributed worldwide; the most important regions of endemicity are the Mediterranean countries, Asia, and Latin America. It has been estimated that the 500,000 new cases ofhuman brucellosis that are reported annually only account for about 4% of the total number of cases [1] , since many cases are either not communicated or are undetected. The disease is a health and economic problem in countries where programs to control cattle infection have been unsuccessful.
Because symptoms of human brucellosis are usually nonspecific, laboratory tests are helpful for establishing the diagnosis. Though the blood culture is the only specific test, its sensitivity ranges from 17% to 85%, depending on the culture conditions and the bacterial strain. This method has a good sensitivity for detecting Brucella melitensis but a low sensitivity for detecting Brucella abortus and Brucella suis [2] . Because of this reason serological tests for diagnosing brucellosis are needed.
Serological tests are based on the use ofeither whole bacteria or antigenic extracts. Among the tests using whole Brucella are the plate agglutination test (Huddleson test), the standard tube agglutination (STA) test with or without 2-mercaptoethanol (2-ME), the rose bengal test, the Coombs' test, and CF. All of these tests mainly detect antibodies to lipopolysaccharide (LPS) [2] . It has been clearly established that these antibodies are responsible for the cross-reactivity with other gram-negative bacteria such as Yersinia enterocolitica 0:9, Escherichia coli 0:157, Salmonella group N, Vibrio cholerae, and Francisella tularensis [3] . On the other hand, agglutination tests have low sensitivity because they are based on secondary interaction and interpretation of their results is largely subjective. The lack of standardization of commercially available Brucella suspensions is another drawback of these tests [4] . ELISA, RIA, and gel precipitation have been developed as tests using antigenic extracts [2] . These tests have improved the sensitivity of detection of antibodies, but the lack of specificity still remains, since the antigenic extracts used in these assays are rich in LPS.
Levels of antibodies to LPS remain high in patients who have recovered from brucellosis [5 -7] , thus making it difficult to differentiate past from present bruceliar infection. Some studies of the changes in values of antibodies to LPS during the disease have been performed [5 -7] . However, to our knowledge, a similar follow-up of antibodies to cytoplasmic proteins of Brucella has not been reported.
We have developed both a capture ELISA and an indirect ELISA that make it possible to independently measure the response of humoral IgG antibodies to LPS and proteins. The antigen used in the indirect ELISA is an extract of cytoplasmic proteins of Brucella; LPS was depleted in this antigen by immunoadsorption with a monoclonal antibody to LPS [8] . We have previously shown that the IgG response to this extract is detected during active human brucellosis but is not detected during inactive brucellosis or infections by cross-reacting bacteria [9] .
Herein, we report the results of our serological follow-up of patients who had active brucellosis with different clinical outcomes; patients were followed up by the capture ELISA, the indirect ELISA, and the STA test with and without 2ME.
Patients and Methods

Patients
Thirty-five patients with active brucellosis who were followed up for a 2-year period at the Brucellosis Department of the F. 1. Muniz Hospital (Buenos Aires) were included in the study. There were 31 men and four women; the patients' ages ranged from 8 to 72 years. STA tests for all the patients were positive (titers of;::: 100 IUImL) at the beginning ofthe disease. 2ME-STA tests were also performed. At the time of diagnosis, blood cultures were performed for all patients, bone marrow cultures were performed for two, and culture of a liver biopsy specimen was performed for one. For those patients for whom bacteriologic isolation was not possible, the diagnosis was established on the basis ofclinical, epidemiologic, and serological data.
At the end of the follow-up, patients were classified into three groups according to the clinical outcome after one or more cycles of antibiotic therapy was administered. Group I included 17 patients who clinically recovered. At the end of the follow-up, these patients were asymptomatic and did not have objective signs of infection. For 11 (65%) of these 17 patients, bacteriologic isolation was possible at the time of diagnosis. Group II included 13 patients who continuously had symptoms that suggested persistent infection. Objective signs of brucellosis were detected in all but two of these patients during the follow-up. Six (46%) of these 13 patients had positive cultures at the time of diagnosis. Group III included five patients who, after an initial recovery, had a clinical relapse associated with a positive blood culture. Brucella was isolated from blood from all five of these patients at the time of diagnosis.
Serum specimens from 30 healthy volunteers with no history of brucellosis or epidemiologic exposure were used as controls in the serological tests.
Serological Tests
Conventional tests. STA and 2ME-STA tests were performed according to the technique of the United States Department of Agriculture (USDA) that was described by Alton et al. [10) ; these authors stated that' 'titers obtained in the USDA test are equal to International Units, e.g., a serum giving + at 1:25 contains 25 IU /mL." Titers were recorded as the last dilution showing "complete" agglutination [10) . Antigens were provided by the Centro Panamericano de Zoonosis-Oficina Panamericana Sanitaria (CPZ-OPS), Buenos Aires.
Determination ofIgG antibodies to LPS. Serum reactivity against LPS and LPS-associated proteins was determined by capture ELISA using the monoclonal antibody to LPS BC68 as described previously [9] . Purified BC68 was adsorbed onto polystyrene plates (Immulon II, Dynatech, Chantilly, VA) with wells containing 50 J-LL of an antibody solution (0.04 mg/ mL) in PBS; the plates were incubated for 1 hour at room temperature. After the plates were washed three times with PBS, adsorption was blocked by the addition of 200 J-LL of a solution of PBS containing 3% skim milk to each well and a I-hour incubation. After blocking the plates were washed with PBS and 0.05% Tween 20 (PBS-T); 10 J-Lg of the cytoplasmic fraction of B. abortus (CYT) was added to each well, and the plate was incubated. Serial dilutions of patients' sera in PBS-T containing 3% skim milk were added to the wells. After 1 hour of incubation, the plates were washed, and specific antibodies were detected with a horseradish peroxidase-conjugated monoclonal antibody to human IgG (Sigma, St. Louis) that was diluted to 1:3,000. Control tests of nonspecific adsorption of antigen with no addition of the capture monoclonal antibody were performed throughout the study. To establish the cutoff value of the assay, 30 serum samples from healthy controls were assayed at a 1: 100 dilution under the same conditions used for patients' sera. The cutoffvalue was calculated as the mean optical density plus 3 SDs.
Determination of IgG antibodies to protein. Serum IgG reactivity against Brucella proteins was determined by indirect ELISA using a preparation of CYT depleted of LPS (LPS-free CYT). This antigen was prepared by immunoadsorption of CYT with BC68 coupled to Sepharose-4B gel (Pharmacia, Piscataway, NJ) as previously described [9] . The plates were sensitized by the addition of 0.5 J-Lg of LPS-free CYT diluted in PBS to each well and a I-hour incubation. Washing, blocking, testing of sera, the second antibody, and starting and stopping of the reaction were performed as described above.
Bacteriologic Studies
The culture medium used was NZ Amine Primatone prepared by CPZ-OPS with reactants from ICN (Costa Mesa, CA). Isolated strains were characterized by means of the phages Tb (Tbsilisi), Bk (Berkeley), and Wb (Weybridge) at two dilutions as previously described by Corbel and Thomas [11) . Typing was performed at the CPZ-OPS; reference strains from the collection of this institution were used.
Other Studies
According to requirements based on the patient's clinical history, biochemical, radiological, ultrasonographic, and histopathologic studies were carried out. Treatment Either a single antibiotic or a combination of antibiotics was used at the following doses: oral doxycycline, 100 mg every 12 hours for 42 days; parenteral streptomycin, 1,000 mg every 24 hours for 21 days; oral rifampin, 300 mg every 12 hours for 42 days; parenteral gentamicin, 2.6 mg/(kg· d) for 10 days; oral oxytetracycline, 500 mg every 6 hours for 42 days; oral ciprofloxacin, 750 mg every 12 hours for 30 days; and oral trimethoprim-sulfamethoxazole, 160 mg/ 800 mg every 8 hours for 30 days.
Doxycycline plus streptomycin or doxycycline plus rifampin was used as initial treatment of 32 patients, and doxycycline plus gentamicin or oxytetracycline plus streptomycin was used as treatment of two patients. Monotherapy with high doses of trimethoprim-su1famethoxazole [12] or ciprofloxacin was given as alternative treatment, as was rifampin plus streptomycin for patients with relapse or persistent illness. Trimethoprimsulfamethoxazole was used as single treatment of one child. None of the patients had received any antibiotic treatment in the 6 months before entering the study. In every case therapy was initiated after the results of the initial serology were available.
Results
Thirty-five patients with different clinical features of active brucellosis were studied. The epidemiologic, clinical, and diagnostic features of these patients are summarized in tables 1, 2, and 3. In 22 cases the diagnosis was confirmed by bacteriologic isolation. Blood culture was positive for 20 patients; the following species were isolated: B. melitensis (6 cases), B. suis (8) , and B. abortus (6) . Bacteriologic isolation was possible from other tissue specimens from two patients with negative blood cultures. B. melitensis was isolated from a bone marrow sample from patient 18, and B. suis was isolated from a hepatic tissue sample from patient 22.
At the time of the diagnosis, the STA tests were positive (~100 IV /mL) for all patients and ELISA revealed values of IgG to cytoplasmic proteins and LPS of~1:200. 2ME-STA tests demonstrated titers of~50 IV /mL for only 19 patients. Twenty-seven individuals (77%) became infected by occupational exposure, and seven (20% ) became infected by ingestion of unpasteurized milk derivatives. In one case (patient 4), the source of infection could not be identified.
The following symptoms were reported: fever, 80% [13 ] were detected: hepatic involvement, orchitis, bone marrow granuloma, pneumonitis, thrombocytopenia, splenic abscess, lumbar epiphysitis, and discopathy. Hepatic involvement-defined as elevated levels of aspartate aminotransferase, alanine aminotransferase, and alkaline phosphatase-was found in 12 patients. Only five of these patients underwent liver biopsy, which showed the following histopathologic results: "viruslike" hepatitis (patient 16), reactive hepatitis (patient 18), granulomatous hepatitis (patients 22 and 23), and cholestatic hepatitis (patient 35). The latter patient had received rifampin therapy before the biopsy. Other laboratory findings included anemia in four patients and thrombocytopenia in one.
Patients were classified into three groups according to the clinical outcome ofbrucellosis after antibiotic treatment. Group I patients recovered, and at the end of the follow-up, they did not have any symptoms or signs ofinfection. Conversely, group II patients, although having received two or more cycles of antibiotic therapy, reported symptoms (asthenia, arthralgia, headache, myalgia, rachia1gia, sweats, and anorexia) during the whole follow-up that suggested persistent infection. Pathological findings related to brucellosis were observed in all but two patients, including hepatomegaly in 4 cases (which was associated with reactive hepatitis in 1 case and with hepatic granuloma in 1 case), splenomegaly in 4 (which was associated with splenic abscess in 1 case), adenopathy in 4, fever in 3, discopathy in 2, and hepatic calcification in 2. Group III patients initially recovered after treatment and had attenuation of symptoms and signs. However, they had clinical relapses with associated positive blood cultures.
The epidemiologic source and the bacterial strain did not differ significantly among the three groups of patients (tables 1-3). However, complications and focalizations were more frequent in patients who had persistent illness (8 of 13) and in those who had clinical relapses (5 of 5) than in patients who recovered (5 of 17).
After the patients were classified according to the clinical outcome of brucellosis, the serological data obtained during the follow-up were retrospectively analyzed. Figure 1 shows the changes in the agglutinin levels measured by STA and 2ME-STA tests in the three groups of patients. Patients who recovered (group I) had a decrease in titers of agglutinating antibodies; this decrease occurred earlier and became more evident when the 2ME-STA test was employed. All these patients had repeatedly negative blood cultures after treatment. Patients with persistent illness (group II) had great individual variability in titers measured by the STA test, which showed low agglutination levels in some cases and exhibited no characteristic reactivity profile. The 2ME-STA test revealed the same findings. At the time of relapse, the STA test demonstrated increased titers of agglutinins in only three of the five group III patients, decreased titers in one, and unchanged titers in one. The 2ME-STA test showed increased titers in four group III patients and a decreased titer in one group III patient at the time of exacerbation of symptoms. (2) lumbar discopathy NOTE. LPS = lipopolysaccharide; 2ME = 2-mercaptoethanol; NO = not determined; STA = standard tube agglutination. All patients who recovered had a decrease in levels of IgG antibodies to proteins, reaching negative values in five cases.
These five patients, however, maintained high values of antibodies to LPS throughout the study. High values (1 :400 to 1: 102,400) of antibodies to proteins were detected in patients with persistent illness throughout the follow-up, while all group III patients had increased values at the time of clinical relapse. A comparison of levels of antibodies to proteins and LPS in the different groups of patients showed that the levels of antibodies to LPS were always higher.
Discussion
We comparatively evaluated different serological methods for determining antibody levels in three groups of patients who had brucellosis with different clinical outcomes after treatment. (1) NOTE. LPS = lipopolysaccharide; 2MB = 2-mercaptoethanol; STA = standard tube agglutination.
* ELISA determining titers ofIgG antibodies to cytoplasmic proteins (expressed as the inverse of the last serum dilution showing a positive result). t ELISA determining titers of IgG antibodies to LPS (expressed as the inverse of the last serum dilution showing a positive result). t Numbers in parentheses indicate the time (mo) elapsed between the beginning of symptoms and the initial sample. § Elevated levels of aspartate aminotransferase, alanine aminotransferase, and alkaline phosphatase.
Group I included patients who recovered, group II included patients with persistent symptoms and signs during the followup, and group III included patients who had relapses during the follow-up. Recovery, persistent active brucellosis, or relapse was independent of both the time elapsed before the diagnosis and the infecting bacterial strain, although it is known that infections caused by B. melitensis and B. suis are more severe and disabling [13] . At the time of diagnosis, the STA test revealed that all patients had titers of~100 IU /mL. Some authors [14] consider any agglutinating antibody titer measured by the 2ME-STA test as indicative of active infection, but others [15] consider that only a titer of~160 IU /mL is "significant evidence of exposure to Brucella antigens." Our experience with>700 treated cases of brucellosis indicates that low antibody levels (~50 IU /mL) are usually present in patients who clinically recover (authors' unpublished data). Thus, we have decided to consider that titers of~50 IU /mL measured by the 2ME-STA test are not significant. We have found low titers (~50 IU /mL) or negative titers in 16 patients with active brucellosis. Moreover, 10 (6 with low titers and 4 with negative titers) of these patients had positive blood cultures at the time the 2ME-STA test was performed. Similar results were previously reported by investigators at our laboratory [16] and are in agreement with those of other authors [2] who question the value of this test as a marker of active infection.
The marked decrease in titers of agglutinating antibodies that were measured by the STA and 2ME-STA tests and were observed in patients who clinically recovered after treatment (group I) is in agreement with findings of previous reports [15] . Some ofthe group II patients had low or negative titers of agglutinating antibodies despite having persistent brucellosis, which is in accordance with the results of Young [17] . These patients, however, had high values of IgG antibodies to LPS measured by ELISA, which may be due to the presence of blocking or incomplete antibodies [7] . At the time of relapse, group III patients had increased, decreased, or no variation in titers measured by the STA test, findings in agreement with those of other authors [7] . Our results confirm that the STA test is seldom useful for detecting relapsing brucellosis. The 2ME-STA test detected relapses in four of the five group III patients, thus representing a higher rate than the rate of 30% reported by Pellicer et al. [7] .
Since low or negative titers of agglutinating antibodies can be observed either in patients with persistent illness or in patients who clinically recover, it is difficult to differentiate these clinical situations by means of STA tests. To assess the presence of active infection in these patients, we used two ELISAs to independently measure responses ofIgG antibodies to proteins and LPS. We have previously shown that the response of IgG to proteins is a good marker of active brucellosis [9, 16] .
Until now, the ELISAs used as serological studies ofbrucellosis have been essentially designed for the detection of different isotypes of immunoglobulins to LPS [5 -7] , but none of these assays eliminated the problem of cross-reactivity with other gram-negative bacteria. Some authors have established that, after treatment, levels of IgM antibodies decrease later than those of IgG antibodies [18] and that, in some cases, low levels can persist for years although no evidence of active infection is noted [19] . However, Ariza et al. [5] found that 12 months after therapy only 25% of patients had a probability of persistence of IgM antibodies to LPS detectable by ELISA. Gazapo et al. [6] reported that values of IgM antibodies to LPS determined by ELISA are not useful for the follow-up of the disease, in spite of being useful for early diagnosis. We found high levels of IgG antibodies to LPS measured by ELISA in patients in groups I and II. Most investigators agree that detection of IgG antibodies to LPS does not differentiate past from present infection [6] and that IgG levels are independent of clinical outcome [5] , since antibodies to LPS can persist from many weeks to years in both exposed and nonexposed patients. On the other hand, healthy people epidemiologically exposed to Brucella may also have high values of antibodies to LPS [20] . Our results agree with those of Ariza et al. [5] in that persistence of IgG is not useful as a marker of chronic infection. Very high levels of IgG could have a predictive value only in cases of focal disease [5] .
All the group III patients had a peak value of IgG antibodies to LPS measured by ELISA at the time of relapse, a finding in agreement with that reported by Pellicer et al. [7] . In accordance with that report, we found that an increase in levels of IgG antibodies to LPS was better detected by ELISA than by the 2ME-STA test because the latter test could not detect one of the relapses.
The usefulness of antibodies to LPS for the diagnosis and serological follow-up of brucellosis can be hindered by their cross-reactivity with other gram-negative bacteria. A rise in levels of antibodies to LPS during follow-up may be due not only to Brucella but also to associated infections with crossreacting bacteria. We have shown that the use of ELISA for measuring levels of antibodies to proteins avoids these drawbacks, thereby making possible the detection of antibodies specific to Brucella [9] .
According to the present study, changes in levels of IgG antibodies to proteins correlate better with clinical recovery than do those in levels of IgG antibodies to LPS. In five of our patients who recovered, levels of IgG antibodies to proteins became negative, while IgG antibodies to LPS persisted in high levels. The levels ofIgG antibodies to proteins in the remaining patients who recovered clearly decreased. While other authors [5] have established that high levels of IgG antibodies to LPS are of no use as predictors of chronicity, we found that levels ofIgG antibodies to proteins were persistently high exclusively in those patients who had chronic infection. No differences in the profiles of antibodies to proteins and LPS were observed in group III patients. According to this finding, antibodies to proteins appear to be as sensitive as antibodies to LPS for detecting relapses [5] .
Our results confirm that serological follow-up of patients by agglutination tests does not always correlate suitably with the clinical outcome of brucellosis. On the other hand, we have found that both ELISAs (measuring antibodies to LPS and proteins) exhibited an adequate correlation with the clinical outcome ofthe patients. However, the detection ofIgG antibodies to proteins is a specific test since it avoids the interference by gram-negative bacteria that cross-react with Brucella LPS. IgG antibodies to proteins are also good markers of recovery, because values of these antibodies become negative in recovered patients in whom high levels of IgG antibodies to LPS persist. These results suggest that the determination of IgG antibodies to cytoplasmic proteins of Brucella could be successfully used as serological follow-up of patients with brucellosis.
